semaglutide faa medical FDA approves obesity drug that helped people cut weight 15% faa semaglutide Drug compounders sue

What Current Evidence and Clinical Trials Tell Us The key published evidence is a 2023 Phase 2 RCT (Jastreboff et al.) showing substantial weight loss and predominantly mild-to-moderate GI side effects

For instance, in September 2025, Novo Nordisk announced that the Phase 3 OASIS 4 trial demonstrated once-daily oral semaglutide 25 mg produced significantly greater weight loss than placebo in adults with overweight or obesity, supporting the advancement of next-generation oral GLP-1 therapies as a convenient alternative to injectable treatments

Design of a randomised, double-blinded, placebo-controlled clinical trial

A more gentle, side-effect-friendly path compared to aggressive medication